THE BEST SIDE OF BLUE CAP CAPSULE

There was no solitary adverse response resulting in discontinuation that occurred in a rate of >2% in CAPLYTA-taken care of sufferers.Concomitant utilization of CAPLYTA with moderate or strong CYP3A4 inhibitors increases lumateperone publicity [see CLINICAL PHARMACOLOGY], which can boost the danger of adverse reactions.Even so, considering that the